Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$11.12 - $22.2 $44,368 - $88,578
-3,990 Reduced 6.9%
53,877 $617,000
Q1 2023

May 15, 2023

BUY
$18.7 - $23.07 $364,967 - $450,257
19,517 Added 50.89%
57,867 $1.17 Million
Q4 2022

Feb 14, 2023

BUY
$18.12 - $27.32 $694,902 - $1.05 Million
38,350 New
38,350 $869,000
Q3 2020

Nov 16, 2020

SELL
$35.98 - $47.66 $161,370 - $213,755
-4,485 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$45.06 - $67.74 $6,894 - $10,364
153 Added 3.53%
4,485 $202,000
Q1 2020

May 15, 2020

BUY
$40.01 - $73.97 $173,323 - $320,438
4,332 New
4,332 $206,000
Q4 2017

Feb 14, 2018

SELL
$9.47 - $19.59 $511,380 - $1.06 Million
-54,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$7.7 - $9.6 $415,800 - $518,400
54,000
54,000 $518,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Weiss Multi Strategy Advisers LLC Portfolio

Follow Weiss Multi Strategy Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.